Last update Jan. 25, 2020
Immunomodulator agent indicated for the treatment of patients affected with highly active relapsing remitting multiple sclerosis.
Oral administration once a day for prolonged periods.
Since the last update we have not found any published data on its excretion in breast milk.
Pharmacokinetic data (large volume of distribution and high protein binding capacity) make it very unlikely its passage to breast milk in significant amounts, but its long half-life could allow it.
Although generally contraindicated in lactation (Langer 2019, Alroughani 2016, Cree 2013, Houtchens 2013), other expert authors consider the use of this medication during lactation probably safe (Briggs 2017).
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in cases of prematurity.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM